133 related articles for article (PubMed ID: 30194082)
1. Indirect Down-regulation of Tumor-suppressive
Saeki N; Saito A; Sugaya Y; Amemiya M; Sasaki H
Cancer Genomics Proteomics; 2018; 15(5):413-420. PubMed ID: 30194082
[TBL] [Abstract][Full Text] [Related]
2. Chromatin Immunoprecipitation and DNA Sequencing Identified a LIMS1/ILK Pathway Regulated by LMO1 in Neuroblastoma.
Saeki N; Saito A; Sugaya Y; Amemiya M; Ono H; Komatsuzaki R; Yanagihara K; Sasaki H
Cancer Genomics Proteomics; 2018; 15(3):165-174. PubMed ID: 29695398
[TBL] [Abstract][Full Text] [Related]
3. FGF represses metastasis of neuroblastoma regulated by MYCN and TGF-β1 induced LMO1 via control of let-7 expression.
Wang XH; Wu HY; Gao J; Wang XH; Gao TH; Zhang SF
Brain Res; 2019 Feb; 1704():219-228. PubMed ID: 30321496
[TBL] [Abstract][Full Text] [Related]
4. Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
Wang K; Diskin SJ; Zhang H; Attiyeh EF; Winter C; Hou C; Schnepp RW; Diamond M; Bosse K; Mayes PA; Glessner J; Kim C; Frackelton E; Garris M; Wang Q; Glaberson W; Chiavacci R; Nguyen L; Jagannathan J; Saeki N; Sasaki H; Grant SF; Iolascon A; Mosse YP; Cole KA; Li H; Devoto M; McGrady PW; London WB; Capasso M; Rahman N; Hakonarson H; Maris JM
Nature; 2011 Jan; 469(7329):216-20. PubMed ID: 21124317
[TBL] [Abstract][Full Text] [Related]
5. Candidate Gene Association Analysis of Neuroblastoma in Chinese Children Strengthens the Role of LMO1.
Lu J; Chu P; Wang H; Jin Y; Han S; Han W; Tai J; Guo Y; Ni X
PLoS One; 2015; 10(6):e0127856. PubMed ID: 26030754
[TBL] [Abstract][Full Text] [Related]
6. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.
Oldridge DA; Wood AC; Weichert-Leahey N; Crimmins I; Sussman R; Winter C; McDaniel LD; Diamond M; Hart LS; Zhu S; Durbin AD; Abraham BJ; Anders L; Tian L; Zhang S; Wei JS; Khan J; Bramlett K; Rahman N; Capasso M; Iolascon A; Gerhard DS; Guidry Auvil JM; Young RA; Hakonarson H; Diskin SJ; Look AT; Maris JM
Nature; 2015 Dec; 528(7582):418-21. PubMed ID: 26560027
[TBL] [Abstract][Full Text] [Related]
7. LMO1 polymorphisms and the risk of neuroblastoma: Assessment of meta-analysis of case-control studies.
Hashemi M; Sarabandi S; Karami S; Śmieja J; Moazeni-Roodi A; Ghavami S; Łos MJ
J Cell Mol Med; 2020 Jan; 24(2):1160-1168. PubMed ID: 31830377
[TBL] [Abstract][Full Text] [Related]
8. LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.
Zhu S; Zhang X; Weichert-Leahey N; Dong Z; Zhang C; Lopez G; Tao T; He S; Wood AC; Oldridge D; Ung CY; van Ree JH; Khan A; Salazar BM; Lummertz da Rocha E; Zimmerman MW; Guo F; Cao H; Hou X; Weroha SJ; Perez-Atayde AR; Neuberg DS; Meves A; McNiven MA; van Deursen JM; Li H; Maris JM; Look AT
Cancer Cell; 2017 Sep; 32(3):310-323.e5. PubMed ID: 28867147
[TBL] [Abstract][Full Text] [Related]
9. ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.
Wang L; Tan TK; Durbin AD; Zimmerman MW; Abraham BJ; Tan SH; Ngoc PCT; Weichert-Leahey N; Akahane K; Lawton LN; Rokita JL; Maris JM; Young RA; Look AT; Sanda T
Nat Commun; 2019 Dec; 10(1):5622. PubMed ID: 31819055
[TBL] [Abstract][Full Text] [Related]
10. LMO1 gene polymorphisms contribute to decreased neuroblastoma susceptibility in a Southern Chinese population.
He J; Zhong W; Zeng J; Zhu J; Zhang R; Wang F; Yang T; Zou Y; Xia H
Oncotarget; 2016 Apr; 7(16):22770-8. PubMed ID: 27009839
[TBL] [Abstract][Full Text] [Related]
11. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
Li D; Mei H; Pu J; Xiang X; Zhao X; Qu H; Huang K; Zheng L; Tong Q
Mol Cancer; 2015 Feb; 14():47. PubMed ID: 25889839
[TBL] [Abstract][Full Text] [Related]
12. Lin28B and Let-7 in the Control of Sympathetic Neurogenesis and Neuroblastoma Development.
Hennchen M; Stubbusch J; Abarchan-El Makhfi I; Kramer M; Deller T; Pierre-Eugene C; Janoueix-Lerosey I; Delattre O; Ernsberger U; Schulte JB; Rohrer H
J Neurosci; 2015 Dec; 35(50):16531-44. PubMed ID: 26674877
[TBL] [Abstract][Full Text] [Related]
13. LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy.
Zhang Y; Yang J; Wang J; Guo H; Jing N
Med Oncol; 2014 Aug; 31(8):99. PubMed ID: 25037573
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
15. LIM domain only 1: an oncogenic transcription cofactor contributing to the tumorigenesis of multiple cancer types.
Zhao GF; Du LQ; Zhang L; Jia YC
Chin Med J (Engl); 2021 Apr; 134(9):1017-1030. PubMed ID: 33870932
[TBL] [Abstract][Full Text] [Related]
16. LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy.
Liu J; Yan P; Jing N; Yang J
Tumour Biol; 2014 Aug; 35(8):8161-7. PubMed ID: 24845030
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.
Soriano A; París-Coderch L; Jubierre L; Martínez A; Zhou X; Piskareva O; Bray I; Vidal I; Almazán-Moga A; Molist C; Roma J; Bayascas JR; Casanovas O; Stallings RL; Sánchez de Toledo J; Gallego S; Segura MF
Oncotarget; 2016 Feb; 7(8):9271-87. PubMed ID: 26824183
[TBL] [Abstract][Full Text] [Related]
18. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma.
Wu T; Lin Y; Xie Z
Biol Res; 2018 May; 51(1):13. PubMed ID: 29793538
[TBL] [Abstract][Full Text] [Related]
20. Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia.
Oram SH; Thoms J; Sive JI; Calero-Nieto FJ; Kinston SJ; Schütte J; Knezevic K; Lock RB; Pimanda JE; Göttgens B
Leukemia; 2013 Jun; 27(6):1348-57. PubMed ID: 23302769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
